Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 5/20 | 1.00 |
| ▸ | FUCA1 | P04066 | 5/20 | 1.00 |
| ▸ | GLA | P06280 | 5/20 | 1.00 |
| ▸ | GANC | Q8TET4 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | AGL | P35573 | 3/20 | 0.93 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.93 |
| ▸ | GBA1 | P04062 | 1/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14654237 | 1.00 | MGAM (1.00) | MGAMFUCA1GLAGANCGAA | |
| SCHEMBL2265529 | 1.00 | MGAM (1.00) | MGAMFUCA1GLAGANCGAA | |
| SCHEMBL2265531 | 1.00 | MGAM (1.00) | MGAMFUCA1GLAGANCGAA | |
| SCHEMBL9379987 | 1.00 | MGAM (1.00) | MGAMFUCA1GLAGANCGAA | |
| SCHEMBL1879685 | 1.00 | MGAM (1.00) | MGAMFUCA1GLAGANCGAA | |
| SCHEMBL20466285 | 1.00 | MGAM (1.00) | MGAMFUCA1GLAGANCGAA | |
| SCHEMBL7824407 | 1.00 | MGAM (1.00) | MGAMFUCA1GLAGANCGAA | |
| SCHEMBL7811568 | 1.00 | MGAM (1.00) | MGAMFUCA1GLAGANCGAA | |
| SCHEMBL18271004 | 1.00 | MGAM (1.00) | MGAMFUCA1GLAGANCGAA | |
| SCHEMBL13298780 | 1.00 | MGAM (1.00) | MGAMFUCA1GLAGANCGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0427694-B1 | Synthesis of mannojirimycin derivatives | MONSANTO CO (US) | 1994-05-04 | — | — | EP | claimed |
| EP-0427694-A1 | Synthesis of mannojirimycin derivatives | MONSANTO COMPANY (US) | 1991-05-15 | — | — | EP | claimed |
| US-5011929-A | From protected azidolactone by reduction and cyclization | MONSANTO COMPANY (US) | 1991-04-30 | — | — | US | claimed |
| CN-111024868-B | Method for detecting content of alpha-high nojirimycin in white tree medicinal material | 华润三九医药股份有限公司 | 2022-06-03 | — | — | CN | disclosed |
| US-20170107180-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. | 2017-04-20 | — | — | US | disclosed |
| US-20170107180-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. | 2017-04-20 | — | — | US | disclosed |
| US-20150299122-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2015-10-22 | — | — | US | disclosed |
| US-20150299122-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2015-10-22 | — | — | US | disclosed |
| US-20150258129-A1 | Method for Increasing the Activity of Lysosomal Enzymes | SINAI SCHOOL MEDICINE (US) | 2015-09-17 | — | — | US | disclosed |
| EP-2027137-B1 | IMINO AND AMINO SUGAR PURIFICATION | AMICUS THERAPEUTICS INC (US) | 2015-02-18 | — | — | EP | disclosed |
| US-8841322-B2 | Method for increasing the activity of lysosomal enzymes | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY (US) | 2014-09-23 | — | — | US | disclosed |
| US-5136036-A | Chemical intermediates | MONSANTO COMPANY (US) | 1992-08-04 | — | — | US | disclosed |
| US-5101027-A | Synthesis of mannojirimycin derivatives | MONSANTO COMPANY (US) | 1992-03-31 | — | — | US | disclosed |
| US-5101027-A | Synthesis of mannojirimycin derivatives | MONSANTO COMPANY (US) | 1992-03-31 | — | — | US | disclosed |
| US-5021562-A | Chemical intermediates | MONSANTO COMPANY (US) | 1991-06-04 | — | — | US | disclosed |
| EP-0427693-A1 | Method for azide displacement of alpha-triflates of 1,5-lactones | MONSANTO COMPANY (US) | 1991-05-15 | — | — | EP | disclosed |
| EP-0427694-A1 | Synthesis of mannojirimycin derivatives | MONSANTO COMPANY (US) | 1991-05-15 | — | — | EP | disclosed |
| EP-0427694-A1 | Synthesis of mannojirimycin derivatives | MONSANTO COMPANY (US) | 1991-05-15 | — | — | EP | disclosed |
| US-5011929-A | From protected azidolactone by reduction and cyclization | MONSANTO COMPANY (US) | 1991-04-30 | — | — | US | disclosed |
| US-5011929-A | From protected azidolactone by reduction and cyclization | MONSANTO COMPANY (US) | 1991-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150258129-A1 | Method for Increasing the Activity of Lysosomal Enzymes | GAA, GBA1, GALC | MGAM 7/4885FUCA1 35/4885GLA 18/4885 |
| US-20150299122-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | OGA, ENGASE, OGT | MGAM 40/4885FUCA1 62/4885GLA 43/4885 |
| US-20170107180-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | OGA, ENGASE, OGT | MGAM 40/4885FUCA1 62/4885GLA 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.